Existing evidence demonstrated that patients with HER2-amplified gastric cancer could benefit from ICIs treatment rather than HER2-amplified breast cancer, and our findings suggest that HER2-amplified LUAD shows higher immunogenicity and a more “inflamed” TIME than HER2-amplified breast cancer and gastric cancer. This evidence concerns the gene ERBB2 and breast carcinoma.